ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 222 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q2 2022. The put-call ratio across all filers is 1.13 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $433 | +279.8% | 12,156 | +390.4% | 0.01% | +400.0% |
| Q2 2023 | $114 | -88.4% | 2,479 | -89.9% | 0.00% | -90.9% |
| Q1 2023 | $982 | -11.1% | 24,486 | +2.8% | 0.01% | -15.4% |
| Q4 2022 | $1,104 | -99.9% | 23,827 | -31.5% | 0.01% | -27.8% |
| Q3 2022 | $1,441,000 | +12.3% | 34,803 | +61.8% | 0.02% | +28.6% |
| Q2 2022 | $1,283,000 | -5.0% | 21,507 | +15.6% | 0.01% | +40.0% |
| Q1 2022 | $1,351,000 | +788.8% | 18,602 | +928.3% | 0.01% | +900.0% |
| Q4 2021 | $152,000 | -15.6% | 1,809 | -9.3% | 0.00% | 0.0% |
| Q3 2021 | $180,000 | -98.6% | 1,994 | -98.5% | 0.00% | -98.4% |
| Q2 2021 | $13,071,000 | +762.2% | 137,084 | +929.4% | 0.06% | +662.5% |
| Q1 2021 | $1,516,000 | +239.1% | 13,317 | +312.3% | 0.01% | +300.0% |
| Q4 2020 | $447,000 | +29.9% | 3,230 | -22.7% | 0.00% | 0.0% |
| Q3 2020 | $344,000 | +9.6% | 4,181 | +4.1% | 0.00% | -33.3% |
| Q2 2020 | $314,000 | -45.7% | 4,017 | -69.1% | 0.00% | -40.0% |
| Q1 2020 | $578,000 | -10.7% | 12,998 | -14.2% | 0.01% | -16.7% |
| Q4 2019 | $647,000 | -22.3% | 15,151 | -22.1% | 0.01% | -14.3% |
| Q3 2019 | $833,000 | +91.9% | 19,461 | +184.8% | 0.01% | +133.3% |
| Q2 2019 | $434,000 | -96.5% | 6,834 | -96.2% | 0.00% | -97.4% |
| Q1 2019 | $12,571,000 | +4488.0% | 181,237 | +2775.4% | 0.12% | +5700.0% |
| Q4 2018 | $274,000 | +138.3% | 6,303 | +320.2% | 0.00% | +100.0% |
| Q3 2018 | $115,000 | -46.3% | 1,500 | -46.1% | 0.00% | -50.0% |
| Q2 2018 | $214,000 | +22.3% | 2,783 | -19.0% | 0.00% | +100.0% |
| Q1 2018 | $175,000 | +20.7% | 3,435 | +10.1% | 0.00% | 0.0% |
| Q4 2017 | $145,000 | -7.1% | 3,120 | +6.5% | 0.00% | 0.0% |
| Q3 2017 | $156,000 | -82.3% | 2,929 | -76.6% | 0.00% | -85.7% |
| Q4 2016 | $880,000 | +12.5% | 12,520 | +13.6% | 0.01% | -12.5% |
| Q3 2016 | $782,000 | +106.3% | 11,021 | +84.0% | 0.01% | +166.7% |
| Q1 2016 | $379,000 | -11.9% | 5,990 | +34.3% | 0.00% | 0.0% |
| Q3 2015 | $430,000 | +194.5% | 4,461 | +213.3% | 0.00% | +200.0% |
| Q2 2015 | $146,000 | -40.7% | 1,424 | -64.1% | 0.00% | 0.0% |
| Q1 2015 | $246,000 | +22.4% | 3,969 | -13.3% | 0.00% | 0.0% |
| Q4 2014 | $201,000 | +45.7% | 4,579 | +88.4% | 0.00% | 0.0% |
| Q3 2014 | $138,000 | – | 2,430 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| GREAT POINT PARTNERS LLC | 727,426 | $25,932,737 | 4.72% |
| RTW INVESTMENTS, LP | 5,405,089 | $192,691,423 | 4.07% |
| First Light Asset Management, LLC | 1,125,032 | $40,107,391 | 3.81% |
| CHI Advisors LLC | 215,000 | $7,664,750 | 3.04% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 250,052 | $8,914,354 | 3.00% |
| SPHERA FUNDS MANAGEMENT LTD. | 259,135 | $9,238,163 | 1.68% |
| Rock Springs Capital Management LP | 1,476,441 | $52,635,122 | 1.41% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 679,459 | $24,222,713 | 1.31% |
| Privium Fund Management B.V. | 115,241 | $4,108,341 | 1.22% |
| SECTOR GAMMA AS | 115,166 | $4,105,668 | 1.05% |